Relationships of inflammatory bowel disease activity with increases in small dense low-density lipoproteins
V. V. Genkel,
Ya. I. Zaripova,
A. S. Sluchanko,
E. V. Lebedev,
L. R. Pykhova,
V. A. Sumerkina,
A. S. Kuznetsova,
A. O. Salashenko,
A. A. Saenko,
S. A. Merkulova,
G. M. Khusainova,
A. I. Dolgushina,
I. I. Shaposhnik https://doi.org/10.21518/ms2025-367
Abstract
Introduction. Chronic immunoinflammatory diseases contribute to modification of circulating lipoproteins, forming atherogenic dyslipidemia, including in the absence of an increase in total and low-density lipoprotein cholesterol (LDL-C). Small Dense Low-Density Lipoprotein-Cholesterol (sdLDL-C) are involved in atherogenic dyslipidemia in patients with inflammatory bowel diseases (IBD). SdLDL-C is a calculated indicator. An LDL-C / Apo B ratio of less than 1.2 indicates the presence of sdLDL-C.
Aim. To evaluate the frequency of a decrease in the LDL-C / Apo B ratio of less than 1.2 and to determine the factors associated with the presence of sdLDL-C in patients with IBD.
Materials and methods. A cross-sectional study was conducted, which included patients with ulcerative colitis and Crohn’s disease aged 40 to 64 years. LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, and ApoB were determined in addition to the standard examination.
Results. 78 patients with IBD were included. A decrease in LDL-C / Apo B of less than 1.2 was detected in 17 (21.8%) patients. A significant decrease in LDL-C/Apo B was found in patients with attack/exacerbation of IBD compared with patients without attack/exacerbation (p = 0.003). An inverse correlation was found between the ratio of LDL-C/Apo B and the endoscopic activity of IBD (r = -0.342; p = 0.002), ESR (r = -0.302; p = 0.012), the number of leukocytes (r = -0.296; p = 0.011) and the concentration of C-reactive protein (r = -0.327; p = 0.007).
Conclusion. The decrease in the LDL-C / apoB ratio was associated with greater endoscopic activity of the disease and an increase in laboratory indicators of inflammation. The share of sdLDL in total LDL-C concentration directly correlated with laboratory and endoscopic indicators of inflammation activity.
About the Authors
V. V. Genkel
South Ural State Medical University
Russian Federation
Russian Federation
Vadim V. Genkel - Dr. Sci. (Med.), Associate Professor, Professor of the Department of Internal Medicine Propaedeutics, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
Ya. I. Zaripova
South Ural State Medical University; City Clinical Hospital No. 1
Russian Federation
Russian Federation
Yana I. Zaripova - Assistant of the Department of Internal Medicine Propaedeutics, South Ural State Medical University; Physician of the Functional Diagnostics Department, City Clinical Hospital No. 1.
64, Vorovskiy St., Chelyabinsk, 454092; 16, Vorovsky St., Chelyabinsk, 454092
A. S. Sluchanko
South Ural State Medical University
Russian Federation
Russian Federation
Alena S. Sluchanko - Assistant of the Department of Hospital Therapy, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
E. V. Lebedev
South Ural State Medical University; City Clinical Hospital No. 1
Russian Federation
Russian Federation
Evgeny V. Lebedev - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Internal Medicine Propaedeutics, South Ural State Medical University; Head of the Department of Functional Diagnostics, City Clinical Hospital No. 1.
64, Vorovskiy St., Chelyabinsk, 454092; 16, Vorovsky St., Chelyabinsk, 454092
L. R. Pykhova
South Ural State Medical University
Russian Federation
Russian Federation
Lubov R. Pykhova - Cand. Sci. (Biol.), Associate Professor of the Department of Microbiology, Virology and Immunology, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
V. A. Sumerkina
South Ural State Medical University
Russian Federation
Russian Federation
Veronika A. Sumerkina - Cand. Sci. (Med.), Associate Professor, Head of the Central Research Laboratory, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
A. S. Kuznetsova
South Ural State Medical University
Russian Federation
Russian Federation
Alla S. Kuznetsova - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Hospital Therapy, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
A. O. Salashenko
South Ural State Medical University
Russian Federation
Russian Federation
Alexey O. Salashenko - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Internal Medicine Propaedeutics, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
A. A. Saenko
South Ural State Medical University
Russian Federation
Russian Federation
Anna A. Saenko - Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
S. A. Merkulova
City Clinical Hospital No. 1
Russian Federation
Russian Federation
Svetlana A. Merkulova - Head of the Gastroenterology Department, City Clinical Hospital No. 1.
16, Vorovsky St., Chelyabinsk, 454092
G. M. Khusainova
South Ural State Medical University
Russian Federation
Russian Federation
Guzel M. Khusainova - Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
A. I. Dolgushina
South Ural State Medical University
Russian Federation
Russian Federation
Anastasia I. Dolgushina - Dr. Sci. (Med.), Professor, Head of the Department of Hospital Therapy, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
I. I. Shaposhnik
South Ural State Medical University
Russian Federation
Russian Federation
Igor I. Shaposhnik - Dr. Sci. (Med.), Professor, Head of the Department of Internal Medicine Propaedeutics, South Ural State Medical University.
64, Vorovskiy St., Chelyabinsk, 454092
References
1. Bikbavova GB, Livzan MA. Cardiovascular risks in patients with inflammatory bowel disease: what should be taken into account? Experimental and Clinical Gastroenterology. 2021;1(6):112–120. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-190-6-112-120.
2. D’Ascenzo F, Bruno F, Iannaccone M, Testa G, De Filippo O, Giannino G et al. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis. Int J Cardiol. 2023;378:96–104. https://doi.org/10.1016/j.ijcard.2023.02.042.
3. Masson W, Fernández-Villar G, Martinez-Elhelou S. Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives. Adv Ther. 2025;42:2118–2134. https://doi.org/10.1007/s12325-025-03154-2.
4. Cainzos-Achirica M, Glassner K, Zawahir HS, Dey AK, Agrawal T, Quigley EMM et al. Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76(24):2895–2905. https://doi.org/10.1016/j.jacc.2020.10.027.
5. Livzan MA, Bikbavova GR, Lisyutenko NS, Romanyuk AE, Drapkina OM. Cardiovascular Risk in Patients with Inflammatory Bowel Diseases – The Role of Endothelial Dysfunction. Diagnostics. 2024;14(16):1722. https://doi.org/10.3390/diagnostics14161722.
6. Isaev GO, Trushina OIu, Isaikina MA, Bestavashvili AA, Yurazh MV, Kopylov PhYu et al The effect of inflammatory bowel diseases on the risk of atherosclerosis: assessment according to ultrasound imaging and sphygmometry. Terapevticheskii Arkhiv. 2025;97(1):29–34. (In Russ.) https://doi.org/10.26442/00403660.2025.01.203028.
7. Nasir K, Acquah I, Dey AK, Agrawal T, Hassan SZ, Glassner K et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey. Am J Prev Cardiol. 2022;9:100316. https://doi.org/10.1016/j.ajpc.2022.100316.
8. Agrawal T, Acquah I, Dey AK, Glassner K, Abraham B, Blankstein R et al. Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2021;6:100171. https://doi.org/10.1016/j.ajpc.2021.100171.
9. Sleutjes JAM, van der Woude CJ, Verploegh PJP, Aribas E, Kavousi M, Roeters van Lennep JE, de Vries AC. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population. Eur J Prev Cardiol. 2023;30(15):1615–1622. https://doi.org/10.1093/eurjpc/zwad124.
10. Alayo QA, Famutimi D, Ayoub M, De Las Fuentes L, Deepak P. Performance of ASCVD Risk Prediction Models in Individuals With Inflammatory Bowel Disease: A UK Biobank Study. Inflamm Bowel Dis. 2025;31(1):285–289. https://doi.org/10.1093/ibd/izae007.
11. D’Ascenzo F, Bruno F, Iannaccone M, Testa G, De Filippo O, Giannino G et al. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis. Int J Cardiol. 2023;378:96–104. https://doi.org/10.1016/j.ijcard.2023.02.042.
12. Wilkinson MJ, Shapiro MD. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay. Arterioscler Thromb Vasc Biol. 2024;44(12):2396–2406. https://doi.org/10.1161/ATVBAHA.124.319983.
13. Poznyak AV, Nikiforov NG, Markin AM, Kashirskikh DA, Myasoedova VA, Gerasimova EV, Orekhov AN. Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis. Front Pharmacol. 2021;11:613780. https://doi.org/10.3389/fphar.2020.613780.
14. Ikezaki H, Lim E, Cupples LA, Liu CT, Asztalos BF, Schaefer EJ. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc. 2021;10(5):e019140. https://doi.org/10.1161/JAHA.120.019140.
15. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313–2330. https://doi.org/10.1093/eurheartj/ehz962.
16. Jin X, Yang S, Lu J, Wu M. Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies. Front Cardiovasc Med. 2022;8:804214. https://doi.org/10.3389/fcvm.2021.804214.
17. Drexel H, Larcher B, Mader A, Vonbank A, Heinzle CF, Moser B et al. The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease. Atherosclerosis. 2021;329:44–49. https://doi.org/10.1016/j.atherosclerosis.2021.05.010.
18. Xiao L, Zhang K, Wang F, Wang M, Huang Q, Wei C, Gou Z. The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids Health Dis. 2023;22(1):104. https://doi.org/10.1186/s12944-023-01869-1.
19. Shelygin YuA, Ivashkin VT, Belousova EA, Reshetov IV, Maev IV, Achkasov SI et al. Ulcerative colitis (K51), adults. Koloproktologia. 2023;22(1):10–44. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-1-10-44.
20. Shelygin YuA, Ivashkin VT, Achkasov SI, Reshetov IV, Maev IV, Belousova EA et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10–49. (In Russ.) https://doi.org/10.33878/2073-7556-2023-22-3-10-49.
21. Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem. 2021;67(7):987–997. https://doi.org/10.1093/clinchem/hvab048.
22. Porsch F, Binder CJ. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2024;21(11):780–807. https://doi.org/10.1038/s41569-024-01045-7.
23. Mortensen MB, Jensen JM, Rønnow Sand NP, Kragholm K, Blaha MJ, Grove EL et al. Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events. J Am Coll Cardiol. 2024;83(25):2643–2654. https://doi.org/10.1016/j.jacc.2024.04.030.
24. Hedar AM, Stradner MH, Roessler A, Goswami N. Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. J Clin Med. 2021;10(19):4427. https://doi.org/10.3390/jcm10194427.
25. Shilova LN, Spitsina SS. Influence of inflammation on lipid profile in chronic rheumatic diseases. Medical Alphabet. 2023;(9):64–69. (In Russ.) https://doi.org/10.33667/2078-5631-2023-9-64-69.
26. Schulte DM, Paulsen K, Türk K, Brandt B, Freitag-Wolf S, Hagen I et al. Small dense LDL cholesterol in human subjects with different chronic inflammatory diseases. Nutr Metab Cardiovasc Dis. 2018;28(11):1100–1105. https://doi.org/10.1016/j.numecd.2018.06.022.
27. Hayashi T, Koba S, Ito Y, Hirano T. Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids Health Dis. 2017;16(1):21. https://doi.org/10.1186/s12944-017-0417-6.
28. Kulanuwat S, Tungtrongchitr R, Billington D, Davies IG. Prevalence of plasma small dense LDL is increased in obesity in a Thai population. Lipids Health Dis. 2015;14:30. https://doi.org/10.1186/s12944-015-0034-1.
29. Tien N, Wu TY, Lin CL, Wu CJ, Hsu CY, Fang YJ, Lim YP. Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study. Front Med. 2022;9:910623. https://doi.org/10.3389/fmed.2022.910623.
30. Sato T, Tanaka M, Furuhashi M. Can small dense LDL cholesterol be estimated from the lipid profile? Curr Opin Lipidol. 2025;36(4):198–202. https://doi.org/10.1097/MOL.0000000000000989.
31. Jung HW, Ra M, Bae HJ, Hong S-P. The LDL-C/Apo B predicts coronary atherosclerotic heart disease in non-diabetic patients without high LDL-C. Medicine. 2023;102(1):e32596. https://doi.org/10.1097/MD.0000000000032596.
32. Sorokin AV, Patel N, Li H, Hong CG, Sampson M, O’Hagan R et al. Estimated sdLDL-C for predicting high-risk coronary plaque features in psoriasis: a prospective observational study. Lipids Health Dis. 2023;22(1):55. https://doi.org/10.1186/s12944-023-01819-x.
Review
For citations:
Genkel VV, Zaripova YI, Sluchanko AS, Lebedev EV, Pykhova LR, Sumerkina VA, Kuznetsova AS, Salashenko AO, Saenko AA, Merkulova SA, Khusainova GM, Dolgushina AI, Shaposhnik II. Relationships of inflammatory bowel disease activity with increases in small dense low-density lipoproteins. Meditsinskiy sovet = Medical Council. 2025;(15):163-170. (In Russ.) https://doi.org/10.21518/ms2025-367
Views:
27
Email this article 